// App-Quantinova.ai

5015 : Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa).

Researchers

Presenter

  • Elahe A. Mostaghel

Principal Investigators

  • Brett Marck

  • Steven P. Balk

  • Philip W. Kantoff

  • Peter Nelson

  • Mary-Ellen Taplin

  • Robert B. Montgomery

  • Alvin M. Matsumoto

  • Daniel Tamae

  • Trevor M. Penning

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Fred Hutchinson Cancer Research Center, Seattle, WADana-Farber Cancer Institute, Boston, MAUniversity of Washington, Seattle, WA

  • University of Pennsylvania, Philadelphia, PA

  • Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health Care System and Department of Medicine, Division of Gerontology & Geriatric Medicine, University of Washington, Seattle, WA

  • VA Puget Sound Healthcare System III, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Apoptotic body index

Drug/Treatment

  • CB-7598

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00924469

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved